Publications
25
Citations
199
Est. group size
~3
Recurring co-author estimate
Active years
11
Publishing since 2015
Priscilla Correa-Jaque's research centers on pulmonary arterial hypertension (PAH), a disease involving high blood pressure in the lung arteries that strains the heart. Her work focuses on improving how doctors predict patient outcomes, using tools like risk stratification models, cardiac imaging, hemodynamic monitoring, and factors such as inflammation, obesity, and heart rate. This research aims to help clinicians better identify low-risk versus high-risk patients and refine treatment decisions.
Publication output was low or absent in the earlier part of the decade but has grown noticeably since 2023, with a marked increase in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes
American Journal of Respiratory and Critical Care Medicine · 2025
- The Prognostic Value of Heart Rate in Patients with Pulmonary Arterial Hypertension
The Journal of Heart and Lung Transplantation · 2025
- A Refined Definition of Low Risk in Patients With Pulmonary Arterial Hypertension Incorporating Mortality and Morbidity
American Journal of Respiratory and Critical Care Medicine · 2025
- Association of Canonical Pathways With Length of Survival in Pulmonary Arterial Hypertension
American Journal of Respiratory and Critical Care Medicine · 2025
- Inflammation and obesity correlate in pulmonary hypertension but associate with diverging outcomes
2025
- Hemodynamically Derived Right Ventricular Diastolic Stiffness Predicts Mortality in Pulmonary Arterial Hypertension
The Journal of Heart and Lung Transplantation · 2024
- Abstract 4144685: External validation and comparison with REVEAL 2.0 of the 6-strata system for risk stratification in PAH: are we reinventing the wheel?
Circulation · 2024
- Abstract 4146364: A refined definition for low-risk pulmonary arterial hypertension patients including mortality and morbidity
Circulation · 2024
- Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?
CHEST Journal · 2023
- Abstract 16736: Comparison of Pulmonary Arterial Hypertension Risk Assessment Tools Using a Harmonized FDA Dataset
Circulation · 2023
- Abstract 13918: Improvement of Pulmonary Arterial Hypertension (PAH) Risk Assessment Model Using Cardiac Magnetic Resonance Imaging Variables
Circulation · 2023
- Abstract 11344: Association of Canonical Pathways with Length of Survival in Pulmonary Arterial Hypertension
Circulation · 2021
- Bayesian Network Modeling: The Future of Pulmonary Arterial Hypertension Risk Stratification Through the PHORA Initiative
2020
- Integrated use of cardiac MRI and the CardioMEMS™ HF system in PAH: the utility of coincident pressure and volume in RV failure—the NHLBI-VITA trial
Cardiovascular Diagnosis and Therapy · 2019
- Hemodynamic Response to Treatment of Iron Deficiency Anemia in Pulmonary Arterial Hypertension: Longitudinal Insights from an Implantable Hemodynamic Monitor
Pulmonary Circulation · 2016
- Circulation×7
- American Journal of Respiratory and Critical Care Medicine×4
- The Journal of Heart and Lung Transplantation×4
- CHEST Journal×2
- Cardiovascular Diagnosis and Therapy×1
- Rebecca Vanderpool
Medicine · The Ohio State University
- Scott Visovatti
Medicine · The Ohio State University
- Raymond L. Benza
Medicine · The Ohio State University
- Andrea L. Frump
Medicine · Indiana University
- Amanda Fisher
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile